Jupiter Topco LLC Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY

Jupiter Topco LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 135,545 shares of the biopharmaceutical company’s stock, valued at approximately $40,808,000. Jupiter Topco LLC owned about 0.10% of Alnylam Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. HM Payson & Co. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $27,000. Golden State Wealth Management LLC lifted its position in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Truist Financial reduced their target price on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Finally, BMO Capital Markets assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, August 19th. They set an “outperform” rating and a $318.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $386.14.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $236.56 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The stock has a market capitalization of $31.65 billion, a P/E ratio of 43.97 and a beta of 0.30. The business has a 50-day moving average price of $263.44 and a two-hundred day moving average price of $294.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the firm earned ($0.51) EPS. The company’s revenue for the quarter was up 66.9% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.